A family history of bowel cancer does not mean that a person will inevitably develop the disease. It can, however, alter the level of risk and the type or timing of screening that should be considered. The significance depends on which relatives were affected, how many were diagnosed, their ages at diagnosis, whether advanced bowel polyps occurred in the family and whether the pattern suggests an inherited cancer syndrome.
For Australians at average risk and without symptoms, national guidance recommends faecal immunochemical testing every two years from age 45 to 74. People aged 45 to 49 can request a free kit through the National Bowel Cancer Screening Program, while eligible people aged 50 to 74 are sent kits automatically. A stronger family history may justify a different strategy, potentially including colonoscopy and an earlier starting age following clinical risk assessment.
Screening applies to people who do not have relevant symptoms. Rectal bleeding, persistent bowel habit changes, unexplained iron-deficiency anaemia, abdominal symptoms or unintended weight loss require medical assessment irrespective of age, family history or the timing of a previous screening test.
Key points
- The effect of family history depends on the number and degree of relatives affected and their ages at diagnosis.
- A first-degree relative is a parent, sibling or child. Their history generally carries more weight than that of a more distant relative.
- Average-risk Australians without symptoms are advised to complete a faecal immunochemical test every two years from age 45 to 74.
- People with a stronger family history may require earlier or more intensive screening, including colonoscopy, based on Australian clinical guidance and individual assessment.
- Symptoms should be investigated rather than managed as routine screening, even when a person is younger than the usual screening age.
Article index
- How does family history affect bowel cancer risk?
- Which relatives matter when assessing risk?
- What family history information should you collect?
- Screening for people at average risk
- When might screening need to begin earlier?
- Screening is different from investigating symptoms
- FIT versus colonoscopy
- Inherited bowel cancer syndromes
- When is genetic counselling considered?
- Do bowel polyps in the family matter?
- What if your previous colonoscopy was normal?
- How to discuss family history with your GP
- Can bowel cancer risk be reduced?
- How Direct Endoscopy can help
- Final thoughts
1. How does family history affect bowel cancer risk?
Most bowel cancers do not arise from a clearly identifiable inherited syndrome. Bowel Cancer Australia reports that approximately 70 per cent of people who develop bowel cancer have no family history of the disease. This is an important reminder that population screening remains relevant even when no relatives have been affected.
Family history nevertheless contributes to risk in a substantial minority of cases. Shared genes can be relevant, but families also share aspects of environment, diet, health behaviour and access to screening. A clustering of cases does not automatically prove that a single inherited mutation is responsible.
The probability of a meaningful familial contribution generally increases when:
- more than one close relative has had bowel cancer
- a relative was diagnosed at a younger age
- bowel cancer has occurred across successive generations
- one person developed multiple primary cancers
- the family includes cancers associated with a recognised hereditary syndrome
- numerous or unusual bowel polyps have been identified
Risk assessment is therefore based on the pattern, not merely the presence or absence of one affected relative. Two people who both report “bowel cancer in the family” may appropriately receive different screening recommendations.
Family history is also dynamic. A person initially assessed as average risk may move into another category if a relative is subsequently diagnosed or new genetic information becomes available. It should be reviewed periodically rather than documented once and forgotten.
2. Which relatives matter when assessing risk?
Clinicians describe relatives by degree because genetic relatedness influences risk assessment.
First-degree relatives are parents, siblings and children. A bowel cancer diagnosis in a first-degree relative generally has greater significance than the same diagnosis in a more distant relative, particularly if the person was young when diagnosed.
Second-degree relatives include grandparents, grandchildren, aunts, uncles, nieces, nephews and half-siblings. Third-degree relatives include first cousins, great-grandparents and great-grandchildren.
The maternal and paternal sides of the family are both relevant. A common error is to report only cancers affecting the parent of the same sex or to assume that bowel cancer inherited through the father’s side is less important. Cancer-predisposition variants can be inherited from either parent.
Biological family history is most directly relevant to inherited risk, but people who are adopted, conceived using donor gametes or estranged from relatives may have incomplete information. Absence of known family history is not always equivalent to confirmed absence of disease in relatives. In these circumstances, the clinician assesses risk using the best available information together with personal medical history and standard population guidance.
3. What family history information should you collect?
A statement such as “my grandfather had bowel problems” is difficult to use clinically. More specific information can materially change the assessment. Where possible, record:
- which biological relative was affected
- the exact type of cancer
- the part of the bowel involved, if known
- age at diagnosis
- whether the person had more than one cancer
- whether advanced adenomas, serrated lesions or numerous polyps were found
- whether genetic testing was performed
- the name of any identified gene variant or syndrome
Family recollection can be inaccurate. “Stomach cancer” may have been used informally to describe bowel, pancreatic, ovarian or another abdominal cancer. When available and appropriate, pathology reports, genetic test results or specialist letters provide more reliable information.
A three-generation family history can help reveal patterns that are not apparent from one relative in isolation. Include both affected and unaffected relatives and their approximate current ages or ages at death. Large and small families require different interpretation because the opportunity to observe cancer differs.
Do not delay all discussion simply because complete records are unavailable. Begin with what is known, identify uncertainties and update the history when further information is obtained.
4. Screening for people at average risk
Population screening is offered to people who feel well, have no relevant symptoms and are not known to be at increased risk. In Australia, current guidance recommends screening with a faecal immunochemical test, commonly called a FIT or iFOBT, every two years from age 45 to 74 for people at average risk.
The FIT detects small quantities of human blood in stool that may not be visible. It is completed at home and does not require bowel preparation, dietary restriction or sedation. A positive result does not diagnose cancer. Blood can arise from several causes, including polyps and non-cancerous conditions, but the source should be investigated. Colonoscopy is commonly recommended after a positive result.
People aged 45 to 49 can request a free kit through the National Bowel Cancer Screening Program. Eligible Australians aged 50 to 74 continue to receive a kit every two years. Completing the test each time it is due matters because a previous negative result does not provide permanent protection.
Colonoscopy is not generally used as the primary population screening test for asymptomatic people at average risk. It is an invasive investigation with preparation, sedation and procedural risks. Its benefits become more favourable when the clinical indication or risk level justifies it.
No screening test provides absolute certainty. FIT is designed to detect blood present at the time the samples are collected, but some cancers and precursor lesions may not bleed continuously. A negative result therefore reduces concern within the screening context but does not guarantee that the bowel is free from disease. This is why the test must be repeated every two years and why symptoms require assessment even after a recent negative result.
A positive FIT result is also not equivalent to a cancer diagnosis. Most people with a positive result will require colonoscopy to establish where the blood originated. Possible explanations include bowel polyps and other non-cancerous conditions. The value of screening lies in identifying people who require further investigation before symptoms have developed, when clinically important disease may be more amenable to treatment.
People should record when each kit was completed and confirm that a result was received. An unreturned kit, an expired kit or a sample that could not be analysed does not constitute completed screening.
5. When might screening need to begin earlier?
There is no single starting age for everyone with a family history. Australian recommendations stratify people according to the pattern of bowel cancer in their family. The strategy can differ from average-risk FIT screening when the estimated risk is higher.
Earlier or more intensive screening may be considered when there are:
- one or more first-degree relatives diagnosed with bowel cancer, particularly at a younger age
- multiple affected relatives on the same side of the family
- both bowel cancer and other syndrome-associated cancers in the family
- numerous adenomas or serrated lesions
- a known pathogenic genetic variant
- a family pattern strongly suggestive of a hereditary syndrome
The recommended test may be FIT, colonoscopy or a syndrome-specific surveillance program. Starting age and interval depend on the precise category. For that reason, informal rules such as “start ten years before your relative was diagnosed” should not be applied without professional assessment. Such principles may form part of some recommendations, but they do not represent the complete Australian guideline framework.
A GP can assess the pedigree, clarify whether the person remains at near-average risk and determine whether gastroenterology or familial cancer service referral is appropriate.
6. Screening is different from investigating symptoms
Screening is designed for people without signs or symptoms. Once symptoms are present, the task is diagnostic assessment, not routine screening. This distinction is particularly important for younger people who assume they must wait until age 45 before discussing bowel symptoms.
Symptoms that warrant medical review can include:
- blood in the stool or rectal bleeding
- a persistent change in bowel frequency or stool form
- unexplained iron-deficiency anaemia
- persistent abdominal pain or swelling
- unintended weight loss
- ongoing fatigue or weakness
- a sensation of incomplete bowel emptying
These symptoms have many possible explanations and often do not indicate cancer. They nevertheless deserve appropriate assessment, especially when persistent, recurrent or unexplained. A negative FIT does not rule out every cause of symptoms and should not be used independently to postpone clinical review.
Family history can lower the threshold for investigation, but absence of family history is not reassuring enough to dismiss significant symptoms. Most people diagnosed with bowel cancer do not report an affected relative.
7. FIT versus colonoscopy
FIT and colonoscopy serve different functions. FIT is a non-invasive population screening test that detects blood in a stool sample. Colonoscopy directly examines the lining of the rectum and colon using a flexible instrument with a camera.
Colonoscopy can:
- identify visible abnormalities
- detect and remove many bowel polyps
- obtain biopsies for pathology
- investigate a positive FIT result
- investigate symptoms or anaemia
- provide surveillance for people at increased risk
Unlike FIT, colonoscopy requires bowel preparation and commonly involves sedation. Bleeding, perforation and sedation-related complications are uncommon but recognised risks. It should therefore be used when clinically indicated rather than assumed to be universally superior for every asymptomatic person.
People referred for colonoscopy can learn more from Direct Endoscopy’s colonoscopy services page and its guide to what to expect before, during and after colonoscopy.
8. Inherited bowel cancer syndromes
A relatively small proportion of bowel cancers are caused by a recognised high-penetrance hereditary syndrome. These conditions are important because they can produce a high lifetime risk, earlier diagnoses and cancers in other organs.
Lynch syndrome results from pathogenic variants affecting DNA mismatch repair. It increases the risk of bowel cancer and several other cancers, including endometrial cancer. Families may show bowel or related cancers across generations, sometimes at younger ages, but family size and incomplete history can obscure the pattern.
Familial adenomatous polyposis is generally associated with the development of numerous adenomatous polyps, often beginning at a young age. Without appropriate management, the risk of bowel cancer is very high. Attenuated forms can present with fewer polyps or at later ages.
Other hereditary polyposis and cancer-predisposition syndromes also exist. The absence of hundreds of polyps does not exclude every genetic condition, and the presence of several polyps does not by itself establish a syndrome.
Syndrome-specific care can involve genetic counselling, testing, colonoscopy at younger ages and screening of other organs. Recommendations for the general population are not sufficient for a person with a confirmed pathogenic variant.
9. When is genetic counselling considered?
Genetic counselling may be appropriate when the family history, age at diagnosis, tumour features or polyp burden raises the possibility of an inherited syndrome. A familial cancer service can review the pedigree, explain the potential benefits and limitations of testing and consider which relative is most informative to test first.
Testing an affected relative is often more informative than beginning with an unaffected family member. If a pathogenic variant is found, targeted testing can then clarify which relatives inherited it. A negative result requires careful interpretation because it may mean that the familial cause was not identified rather than proving that no inherited susceptibility exists.
Genetic information can have implications beyond the person tested. It may affect children, siblings and other relatives and can raise questions about communication, privacy, insurance and reproductive planning. Pre-test counselling supports informed consent and realistic expectations.
Not everyone with one older relative who developed bowel cancer needs genetic testing. Referral decisions are based on established criteria and clinical judgement.
10. Do bowel polyps in the family matter?
Some bowel polyps are recognised precursor lesions from which cancer can develop over time. A history of advanced adenomas, advanced serrated lesions or numerous polyps in a close relative may therefore contribute to risk assessment, particularly when identified at a younger age.
The term “polyp” alone is not sufficiently specific. Hyperplastic polyps, adenomas and sessile serrated lesions do not all have the same implications. Size, number, location and microscopic features matter. If possible, obtain the colonoscopy or pathology details rather than relying on a relative’s recollection that “a few polyps” were removed.
When a person undergoes colonoscopy and has polyps removed, the future interval is determined by their own complete findings. Direct Endoscopy’s article on colonoscopy results, polyps and biopsies explains how pathology contributes to follow-up planning.
11. What if your previous colonoscopy was normal?
A high-quality normal colonoscopy can be reassuring, but it does not eliminate lifetime risk. Future screening depends on why the procedure was performed, whether the examination was complete, the quality of bowel preparation, the family history and whether new symptoms develop.
A person may still need planned screening or surveillance after a normal result. The interval should be documented by the treating clinician rather than estimated from a general online timetable.
Changes in family history can also affect future planning. If a close relative is subsequently diagnosed at a young age or a pathogenic variant is identified, advise the GP even if the previous colonoscopy was normal.
New symptoms should be assessed when they occur. A future surveillance date does not mean that bleeding, anaemia or a persistent bowel change should wait until that appointment.
12. How to discuss family history with your GP
Book a routine appointment specifically to review bowel cancer risk if the history is complex. Bring a written summary and, where available, copies of pathology, genetic or specialist reports.
Useful questions include:
- Does my family history place me at near-average, moderate or high risk?
- Should I use FIT, colonoscopy or another strategy?
- At what age should I begin, and what interval applies?
- Do I meet criteria for gastroenterology or genetic referral?
- Are there records from my affected relative that would clarify the assessment?
- What symptoms should prompt investigation between planned screening tests?
Tell the GP about personal polyps, inflammatory bowel disease, previous cancer and all relevant symptoms. Risk assessment is not based on family history alone.
13. Can bowel cancer risk be reduced?
Genes and family history cannot be changed, but risk is not determined by inheritance alone. Avoiding smoking, limiting alcohol, maintaining regular physical activity, supporting a healthy body weight and following a balanced diet can contribute to overall health and may reduce bowel cancer risk.
Lifestyle measures do not replace screening. A person can be physically active, eat well and still develop bowel cancer. Conversely, risk factors do not mean that cancer is inevitable.
The most practical risk-management steps are to understand the family history, discuss it with a clinician, participate in the recommended screening program and investigate symptoms promptly. Screening is effective only when it is completed at the advised intervals and positive results receive appropriate follow-up.
14. How Direct Endoscopy can help
Direct Endoscopy provides specialist-led colonoscopy services across Melbourne, with facilities in Frankston, Hampton, Bayswater, Narre Warren and Rosebud.
If your GP recommends colonoscopy because of family history, symptoms, a positive bowel screening test or previous polyps, review the appointment information and hospital locations. Direct Endoscopy also provides information about bowel cancer risk, diagnosis and prevention.
Patients preparing for their appointment can read how long the colonoscopy appointment and recovery process may take and review the guide to colonoscopy aftercare.
15. Final thoughts
Family history is not a simple yes-or-no risk factor. The number and degree of affected relatives, their ages at diagnosis, the types of cancers and polyps involved and any genetic findings all contribute to the appropriate screening strategy.
For average-risk Australians without symptoms, FIT screening is recommended every two years from age 45 to 74. A stronger family pattern may justify earlier or more intensive surveillance, but the starting age and test should be determined through clinical risk assessment.
Screening is not an appropriate response to active symptoms. Rectal bleeding, persistent bowel changes, unexplained iron-deficiency anaemia, unintended weight loss or other concerning features should be discussed with a doctor without waiting for the next screening round.
This article provides general information and does not replace individual medical advice. In a medical emergency, call Triple Zero (000).